Sai Parenteral Limited and Hella Infra Market have received Sebi approval for their IPOs. Sai Parenteral's offering includes a ₹285 crore fresh issue and OFS of 35,00,000 shares, with proceeds allocated for capacity expansion, R&D centre establishment, debt repayment, and subsidiary investment. The pharmaceutical company operates across multiple therapeutic segments and began exports in fiscal 2023.
Sai Parenteral and Hella Infra Market Receive Sebi Approval for Initial Public Offerings
